pediatric nephrology (berlin, germany)

Journal of clinical and experimental hepatology

[1] Management of dyslipidemia in pediatric renal transplant recipients.

[2] Determinants of Medication Adherence in Liver Transplant Recipients.

[3] Uterus Transplantation with Live Donors: Screening Candidates in One French Center

[4] machine perfusion of porcine livers with oxygen-carrying solution results in reprogramming of dynamic inflammation networks

[5] transplantation assessment of degraded posidonia oceanica habitats: site selection and long-term monitoring

[6] development of new method and protocol for cryopreservation related to embryo and oocytes freezing in terms of fertilization rate: a comparative study including review of literature

[7] medical image of the week: bronchial clot removal via cryotherapy

[8] Foliar anthocyanin accumulation may be a useful indicator of hardiness in eucalypt seedlings

[9] Potential drug-drug interactions of immunosuppressants in kidney transplant recipients: comparison of drug interaction resources

[10] Face Transplantation and Identity: Hidden Identities, Exceptions, and Exclusions.

[11] Acute Renal Transplant Failure Secondary to an Obstructing Ileal Conduit Adenocarcinoma: Case Report and Literature Review.

[12] Successful eradication of chronic symptomatic Candida krusei urinary tract infection with increased dose micafungin in a liver and kidney transplant recipient: Case report and review of the literature.

[13] Why do lung transplant patients discontinue triazole prophylaxis?

[14] Interventions to Prevent Nonmelanoma Skin Cancers in Recipients of a Solid Organ Transplant: Systematic Review of Randomized Controlled Trials.

[15] Exercise training is safe and feasible in patients awaiting liver transplantation: a pilot randomized controlled trial.

[16] Kidney transplantation from living donors with multiple renal arteries

[17] Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology

[18] Impact of pre-transplant infection management on the outcome of living-donor liver transplantation in Egypt

[19] Invasive pulmonary infection due to Thermoascus crustaceus in a kidney transplant recipient

[20] Genetic diversity and antibiotic susceptibility of uropathogenic Escherichia coli isolates from kidney transplant recipients

[21] Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review

[22] Comparative effectiveness of antifungal agents in patients with hematopoietic stem cell transplantation: a systematic review and network meta-analysis

[23] Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy

[24] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[25] Pseudomonas aeruginosa bacteremia among liver transplant recipients

[26] Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation

[27] Epidemiology, susceptibility, and risk factors for acquisition of MDR/XDR Gram-negative bacteria among kidney transplant recipients with urinary tract infections

[28] Methicillin-resistant Staphylococcus aureus bacteremia among liver transplant recipients: epidemiology and associated risk factors for morbidity and mortality

[29] Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

[30] Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

[31] Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt

[32] Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

[33] Impact of pre-transplant infection management on the outcome of living-donor liver transplantation in Egypt

[34] Invasive pulmonary infection due to Thermoascus crustaceus in a kidney transplant recipient

[35] Genetic diversity and antibiotic susceptibility of uropathogenic Escherichia coli isolates from kidney transplant recipients

[36] Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review

[37] Impact of pre-transplant infection management on the outcome of living-donor liver transplantation in Egypt

[38] Invasive pulmonary infection due to Thermoascus crustaceus in a kidney transplant recipient

[39] Genetic diversity and antibiotic susceptibility of uropathogenic Escherichia coli isolates from kidney transplant recipients

[40] Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review

[41] Pros and Cons of Aspirin Prophylaxis for Prevention of Cardiovascular Events in Kidney Transplantation and Review of Evidence

[42] Dermatological Disorders following Liver Transplantation: An Update

[43] The Effects of Fecal Donors with Different Feeding Patterns on Diarrhea in a Patient Undergoing Hematopoietic Stem Cell Transplantation

[44] Comparative effectiveness of antifungal agents in patients with hematopoietic stem cell transplantation: a systematic review and network meta-analysis

[45] Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy

[46] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[47] Pseudomonas aeruginosa bacteremia among liver transplant recipients

[48] Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation

[49] Epidemiology, susceptibility, and risk factors for acquisition of MDR/XDR Gram-negative bacteria among kidney transplant recipients with urinary tract infections

[50] Methicillin-resistant Staphylococcus aureus bacteremia among liver transplant recipients: epidemiology and associated risk factors for morbidity and mortality

[51] Gastric Mucormycosis in a Renal Transplant Patient Treated with Isavuconazole Monotherapy

[52] Postinfectious Acute Glomerulonephritis in Renal Transplantation: An Emergent Aetiology of Renal Allograft Loss

[53] Unusual Presentation of Hemophagocytic Lymphohistiocytosis in a Kidney Transplant Patient

[54] An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient

[55] Deceased Donor Renal Transplantation Combined with Bilateral Nephrectomy in a Patient with Tuberous Sclerosis and Renal Failure

[56] The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis

[57] Segmental Distribution of Hepatocellular Carcinoma Correlates with Microvascular Invasion in Liver Explants Undergoing Transplantation

[58] Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

[59] Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

[60] Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt

[61] Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

[62] Vectisol Formulation Enhances Solubility of Resveratrol and Brings Its Benefits to Kidney Transplantation in a Preclinical Porcine Model.

[63] Emerging therapeutic strategies for transplantation-induced acute kidney injury: protecting the organelles and the vascular bed.

[64] Acute Kidney Injury in Pregnant Patient With Pancreas-Kidney Transplant Caused by Abdominal Compartment Syndrome: A Case Presentation, Review of Literature, and Proposal of Diagnostic Approach.

[65] Heavy metal accumulation and phytoremediation potential by transplants of the seagrass Zostera marina in the polluted bay systems

[66] Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency Diseases: Current Status and Future Perspectives.

[67] Voriconazole tolerability in lung transplant recipients: Is N-oxide metabolite responsible for phototoxicity?

[68] Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations.

[69] Negative impact of recipient SPRED2 deficiency on transplanted lung in a mouse model.

[70] Randomized Controlled Trial Assessing the Impact of Everolimus and Low Exposure Tacrolimus on Graft Outcomes in Kidney Transplant Recipients.

[71] Fecal metabolite of a gnotobiotic mouse transplanted with gut microbiota from a patient with Alzheimer's disease.

[72] Human Herpesvirus 6B and Lower Respiratory Tract Disease After Hematopoietic Cell Transplantation.

[73] Roles of Epstein–Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation

[74] Challenging hepatitis C-infected liver transplant patients

[75] Incidence and outcome of Kaposi sarcoma after hematopoietic stem cell transplantation: a retrospective analysis and a review of the literature, on behalf of infectious diseases working party of EBMT.

[76] Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study

[77] Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR-inhibitors: 1997–2016

[78] Imaging of Kaposi sarcoma in a transplanted liver: A rare case report

[79] Proactive treatment of angiotensin receptor antibodies in kidney transplantation with plasma exchange and/or candesartan is safe and associated with excellent graft survival at 4 years: A single centre Australian experience

[80] Effects of telmisartan and candesartan on the metabolism of lipids and glucose in kidney transplant patients: A prospective, randomized crossover study

[81] [Relation between renal transplantation and work situation].

[82] Recent advances in understanding and managing infectious diseases in solid organ transplant recipients.

[83] HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.

[84] Incidence of and risk factors for cryptococcosis in kidney transplant recipients in Taiwan- a nationwide population-based study.

[85] A novel automated transplanting system for plant tissue culture

[86] Bone-Plug Versus Soft Tissue Fixation of Medial Meniscal Allograft Transplants: A Biomechanical Study.

[87] Sex and Gender Considerations in Transplant Research: A Scoping Review.

[88] Exercise for Solid Organ Transplant Candidates and Recipients: A Joint Position Statement of the Canadian Society of Transplantation and CAN-RESTORE.

[89] Kidney transplantation. Experience at the University Hospital José E. González, UANL in Monterrey, Mexico

[90] Application of Machine-Learning Models to Predict Tacrolimus Stable Dose in Renal Transplant Recipients.

[91] Protocol-Based Nurse Coordinator Management of Ambulatory Tacrolimus Dosing in De Novo Renal Transplant Recipients - A Single Center Experience with a Large African American Population.

[92] Predictors of Meniscal Allograft Transplantation Outcome: A Systematic Review.

[93] Induction of Accommodation by Anti-complement Component 5 Antibody-based Immunosuppression in ABO-incompatible Heart Transplantation.

[94] Defining the Burden of Emergency General Surgery in Transplant Patients: A Nationwide Examination

[95] Combined Thoracic and Abdominal Organ Transplantation: Special Considerations.

[96] Outcomes of Vascularized Bone Allotransplantation with Surgically Induced Autogenous Angiogenesis in a Large Animal Model: Bone Healing, Remodeling, and Material Properties.

[97] Commentary on “FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study”

[98] A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

[99] Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencing.

[100] A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant.

[101] Experimental small bowel transplantation from non-heart-beating donors: a large-animal study.